AmerisourceBergen Corp. (NYSE:ABC) insider Dale Danilewitz sold 3,121 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $92.12, for a total value of $287,506.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Dale Danilewitz also recently made the following trade(s):

  • On Monday, November 20th, Dale Danilewitz sold 4,459 shares of AmerisourceBergen stock. The stock was sold at an average price of $78.30, for a total value of $349,139.70.
  • On Monday, November 13th, Dale Danilewitz sold 1,857 shares of AmerisourceBergen stock. The shares were sold at an average price of $74.69, for a total transaction of $138,699.33.
  • On Thursday, November 2nd, Dale Danilewitz sold 2,012 shares of AmerisourceBergen stock. The shares were sold at an average price of $74.99, for a total transaction of $150,879.88.
  • On Thursday, October 5th, Dale Danilewitz sold 2,012 shares of AmerisourceBergen stock. The shares were sold at an average price of $85.00, for a total transaction of $171,020.00.

Shares of AmerisourceBergen Corp. (NYSE:ABC) traded up $0.35 during trading hours on Wednesday, hitting $94.39. 1,035,206 shares of the company were exchanged, compared to its average volume of 1,700,000. The company has a current ratio of 0.91, a quick ratio of 0.48 and a debt-to-equity ratio of 1.83. AmerisourceBergen Corp. has a 1 year low of $71.90 and a 1 year high of $97.85. The company has a market cap of $20,580.00, a P/E ratio of 58.27, a price-to-earnings-growth ratio of 1.59 and a beta of 0.99.

AmerisourceBergen (NYSE:ABC) last announced its quarterly earnings results on Thursday, November 2nd. The company reported $1.33 EPS for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.01. AmerisourceBergen had a net margin of 0.27% and a return on equity of 56.29%. The firm had revenue of $39.12 billion during the quarter, compared to the consensus estimate of $40.10 billion. During the same quarter last year, the firm earned $1.30 EPS. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. equities research analysts predict that AmerisourceBergen Corp. will post 6.07 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Monday, December 4th. Investors of record on Monday, November 20th were issued a $0.38 dividend. This is an increase from AmerisourceBergen’s previous quarterly dividend of $0.37. The ex-dividend date of this dividend was Friday, November 17th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 1.61%. AmerisourceBergen’s dividend payout ratio (DPR) is presently 93.83%.

Several research firms have commented on ABC. Zacks Investment Research raised shares of AmerisourceBergen from a “hold” rating to a “buy” rating and set a $105.00 price objective for the company in a report on Wednesday. Needham & Company LLC increased their price objective on shares of AmerisourceBergen from $86.00 to $88.00 and gave the company a “buy” rating in a report on Wednesday, November 22nd. Royal Bank of Canada began coverage on shares of AmerisourceBergen in a report on Tuesday, September 19th. They set a “sector perform” rating and a $87.00 price objective for the company. Morgan Stanley downgraded shares of AmerisourceBergen from an “overweight” rating to an “equal weight” rating in a report on Thursday, September 14th. Finally, Leerink Swann set a $105.00 price objective on shares of AmerisourceBergen and gave the company a “buy” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, six have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $95.26.

Several large investors have recently made changes to their positions in ABC. JPMorgan Chase & Co. lifted its holdings in shares of AmerisourceBergen by 107.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,363,429 shares of the company’s stock valued at $434,385,000 after acquiring an additional 2,776,287 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of AmerisourceBergen by 660.8% in the 2nd quarter. Janus Henderson Group PLC now owns 2,574,746 shares of the company’s stock valued at $243,392,000 after acquiring an additional 2,236,319 shares during the last quarter. Harding Loevner LP lifted its holdings in shares of AmerisourceBergen by 89.6% in the 3rd quarter. Harding Loevner LP now owns 3,166,794 shares of the company’s stock valued at $134,939,000 after acquiring an additional 1,496,761 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of AmerisourceBergen by 42.9% in the 2nd quarter. Wells Fargo & Company MN now owns 3,344,441 shares of the company’s stock valued at $316,149,000 after acquiring an additional 1,003,327 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in AmerisourceBergen in the third quarter worth about $75,681,000. 67.83% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This report was posted by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/03/amerisourcebergen-corp-abc-insider-dale-danilewitz-sells-3121-shares.html.

AmerisourceBergen Company Profile

AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company’s segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers.

Insider Buying and Selling by Quarter for AmerisourceBergen (NYSE:ABC)

Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.